Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > If he has 1200000 shares
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Oct 19, 2021 5:05pm
351 Views
Post# 34024556

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:If he has 1200000 shares

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:If he has 1200000 sharesYou'd know if you were here long enough.


StockingUp21 wrote:

what account is this muggy?

 

drippingsnot wrote: I don't know Stockings ... if you knew me ... you'd know my tagline ...

I'm either going to be really happy with this one or I'm going to cry like a littel baby !

How am I wrong about that ?

Get over it !!!!



----------------------

We're all feeling it now and what you'd like to do is find a scapegoat.
You're in this as much as the rest of us ... so stop worrying about right and wrong  ... true and false ... burn him at the stake !!!  You live that life all you want.

I'm playing it like it was October 6, 2017 all over again.

But ... make no mistake Stockings ... I'm not asking for your computer credentials or your credit card.  I shop alone.
 

 

 



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities